Dr. Lal PathLabs Ltd

Dr. Lal PathLabs Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. For Q2 FY27, the company reported a consolidated revenue of ₹874 Cr, a 19.6% increase year-on-year. EBITDA grew by 25.1% to ₹280 Cr with a margin of 32.1%, and Profit After Tax (PAT) rose by 27.5% to ₹194 Cr, achieving a margin of 22.2%. For the half-year ended FY27, revenue increased by 19.4% to ₹1,672 Cr, EBITDA by 26.7% to ₹528 Cr, and PAT by 27.3% to ₹364 Cr. The company also declared an interim dividend of 50%, or ₹5 per share. Cash and cash equivalents stood at ₹1,746 Cr as of September 30, 2026.

Dr. Lal PathLabs Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also declared a second interim dividend of INR 5 per equity share for FY 2026-27, with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director (Non-Executive Independent Director) for a three-year term, subject to shareholder approval. The company also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business operations and investments in its own subsidiary, Sunshine Healthcare Limited (SHL), Ghana.

Dr. Lal PathLabs Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also declared a second interim dividend of INR 5 per equity share for FY 2026-27, with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director (Non-Executive Independent Director) for a three-year term, subject to shareholder approval. The company also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business operations and investments in its own subsidiary, Sunshine Healthcare Limited (SHL), Ghana. The Board meeting took place on November 04, 2026.

Dr. Lal PathLabs Ltd announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also declared a second interim dividend of INR 5 per equity share for the financial year 2026-27, with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director (Non-Executive Independent Director) for a three-year term, subject to shareholder approval. The company also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business and operational needs, including further investment in its subsidiary Sunshine Healthcare Limited (SHL), Ghana. The Board meeting commenced at 11:49 AM IST and concluded at 01:20 PM IST.

Dr. Lal PathLabs Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also declared a second interim dividend of INR 5 per equity share for the financial year 2026-27, with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director (Non-Executive Independent) for a three-year term, subject to shareholder approval. The company also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business operations and investments in its own subsidiary, Sunshine Healthcare Limited (SHL), Ghana. The Board meeting commenced at 11:49 AM IST and concluded at 01:20 PM IST.

Dr. Lal PathLabs Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors declared a second interim dividend of INR 5 per equity share for FY2026-27, with a record date of November 11, 2026. Additionally, the company approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business and operational needs, including further investment in its subsidiary Sunshine Healthcare Limited (SHL), Ghana. The Board also approved the appointment of Ms. Vasuta Agarwal as an Additional Director, designated as a Non-Executive Independent Director, for a term of three years, subject to shareholder approval.

Dr. Lal PathLabs Ltd announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also declared a second interim dividend of INR 5 per equity share for FY 2026-27, with a record date of November 11, 2026. Additionally, Ms. Vasuta Agarwal was appointed as an Additional Director (Non-Executive Independent Director) for a three-year term, subject to shareholder approval. The company also approved a further investment of up to INR 49.5 Crores in its wholly-owned subsidiary, Dr. Lal PathLabs FZCO (LPL Dubai), to support its business operations and investments in its own subsidiary, Sunshine Healthcare Limited (SHL), Ghana.

Dr. Lal PathLabs' consolidated revenue rose 19.6% YoY (9.5% QoQ) to ₹873.9 Cr in Q2 FY27, with consolidated PAT up 27.4% YoY (13.7% QoQ) to ₹193.9 Cr. There were no exceptional items in either this quarter or the year-ago quarter, so reported and underlying growth are identical — unlike FY26's full year, which carried a ₹30.1 Cr one-off Labour Codes charge. The print runs ahead of management's own guidance from the Q1 FY27 call, where revenue growth was informally upgraded to "trending mid-teens"; at 19.6% YoY, this quarter clears that bar comfortably and also accelerated from Q1's 19.1% YoY pace. Margins expanded on both lines: operating margin (EBITDA excluding other income, over revenue) came in at 32.1%, up ~140 bps YoY and ~100 bps QoQ, while net margin rose to 21.4%, up 120 bps YoY and 80 bps QoQ. That expansion is notable because management had flagged no formal EBITDA margin upgrade last quarter, saying it would reinvest topline upside into expansion rather than bank it as margin — operating leverage from the higher revenue base evidently outpaced that reinvestment spend. Standalone PAT grew a slower 23.1% YoY to ₹179.7 Cr versus consolidated's 27.4%, a ~4-point gap pointing to a stronger contribution from subsidiaries this quarter (newly consolidated Shahbazkers Diagnostic Centre and the Ghana-based Sunshine Healthcare stake). Basic EPS was ₹11.51, on a post-bonus base of roughly 16.78 Cr shares following the December 2025 1:1 bonus issue. No specific Street consensus estimate for this quarter could be located in available previews or brokerage notes, so this print cannot be benchmarked against a published number; full-year FY27 consensus EPS stood at ₹37.00 (+15.6%) ahead of this result, for context only. Management's own framing wasn't available beyond the procedural board-outcome letter — no press release commentary was furnished with this filing. The quarter was accompanied by continued inorganic activity: the Board approved up to ₹49.5 Cr of further investment in Dubai subsidiary LPL Dubai (which itself holds the Ghana stake); the company completed a 70% acquisition of SN Genelab for up to ₹168 Cr plus a ₹31.5 Cr earn-out (effective October 1); and a subsidiary spent ₹30.3 Cr to buy out the remaining 30% of Centrapath Labs, making it wholly owned. The Board also declared a second interim dividend of ₹5/share (record date November 11), taking FY27 interim payouts to ₹10/share so far. Separately, the Income Tax Department has filed an ITAT appeal against the company; no financial impact was quantified in the filing. Going into H2 FY27, management's FY27 capex guidance of ₹140–150 Cr (raised from ₹100–120 Cr) and plans for 12–15 new labs and 3–4 radiology centers remain the stated roadmap, alongside its promise to reassess revenue/margin guidance from Q2 onward — a formal update, given this quarter's outperformance, is a logical next checkpoint. SN Gene and the Ghana business will also start contributing to consolidated numbers from Q3 FY27.

Dr. Lal PathLabs Ltd has announced that its Board of Directors will convene on November 4, 2026. The meeting's agenda includes the consideration and approval of the un-audited standalone and consolidated financial results for the Quarter and Half Year ended September 30, 2026. Additionally, the Board will evaluate the declaration of a second interim dividend, if any, for the Financial Year 2026-27. This meeting follows up on a previous intimation dated September 25, 2026.

Dr. Lal PathLabs Ltd has announced that its Board of Directors will convene on Wednesday, November 04, 2026. The primary agenda items include the consideration and approval of the un-audited financial results (Standalone & Consolidated) for the Quarter and Half Year ended September 30, 2026. Additionally, the Board will evaluate the possibility of declaring a second interim dividend for the Financial Year 2026-27 on the company's equity shares. This meeting follows a previous intimation dated September 25, 2026.